Roche skin cancer drugs "too expensive", says UK cost agency

LONDON, June 16 (Reuters) - Roche's two-drug combination of Cotellic and Zelboraf for melanoma was rejected by Britain's healthcare cost agency NICE as "too expensive" on Thursday, in contrast to the green light given in April to a rival cocktail from Novartis.

from Reuters: New Issues News http://ift.tt/1tydCWP